Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: Final results

Journal of Infectious Diseases

Volumn 204, Issue 8, 2011, Pages 1191-1201

  Sax, Paul E ^a   Tierney, Camlin ^b   Collier, Ann C ^c   Daar, Eric S ^d   Mollan, Katie ^b   Budhathoki, Chakra ^b   Godfrey, Catherine ^e   Jahed, Nasreen C ^f   Myers, Laurie ^g   Katzenstein, David ^h   Farajallah, Awny ⁱ   Rooney, James F ^j   Ha, Belinda ^k   Woodward, William C ^l   Feinberg, Judith ^m   Tashima, Karen ⁿ   Murphy, Robert L ^o   Fischl, Margaret A ^p  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^g FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j GILEAD SCIENCES   (United States)

^k GLAXOSMITHKLINE   (United States)

^l ABBOTT LABORATORIES   (United States)

^m UNIVERSITY OF CINCINNATI   (United States)

ⁿ BROWN UNIVERSITY   (United States)

^o NORTHWESTERN UNIVERSITY   (United States)

^p UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; CD4 ANTIGEN; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; PLACEBO; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ARTICLE; ASTHENIA; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FOLLOW UP; FRACTURE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA AND VOMITING; NEUTROPHIL COUNT; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DOUBLE-BLIND METHOD; FEMALE; HIV; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RNA, VIRAL; VIRAL LOAD;

EID: 80052897871     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir505     Document Type: Article

References (17)

1. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321-33.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, 2011; 1-174. http://aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL.pdf. Accessed 28 August 2011.
3. DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004; 39:1038-46. Epub 2004. (Pubitemid 39313463)
4. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-60. (Pubitemid 43113030)
5. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV therapy. N Engl J Med 2009; 361:2230-40. Epub 2009.
6. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV: spring 2008. Top HIV Med 2008; 16:62-8.
7. dePerio MA, Gomez FJ, Frame PT, Fichtenbaum CJ. A Truvada hypersensitivity reaction simulating abacavir hypersensitivity. AIDS 2007; 21:3-2252. 29.
8. Rousseau FS, Wakeford C, Mommeja-Marin H, et al. Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. J Infect Dis 2003; 188:1652-8. Epub 2003. (Pubitemid 38010675)
9. Maserati R, De Silvestri A, Uglietti A, et al. Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine. AIDS 2010; 24:1013-8.
10. Trivedi V, Von Lindern J, Montes-Walters M, et al. Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility. AIDS Res Hum Retroviruses 2008; 24:1291-300.
11. Hawkins T, Veikley W, St Claire RL 3rd, Guyer B, Clark N, Kearney BP. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr 2005; 39:406-11. (Pubitemid 41003784)
12. Nelson M, Girard PM, Demasi R, et al. Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data. J Antimicrob Chemother 2010; 65:1505-9.
13. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008; 197:102-8. (Pubitemid 351263473)
14. Fux CA, Simcock M, Wolbers M, et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 2007; 12:1165-73.
15. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568-79.
16. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009; 23:1547-6.
17. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010; 55:49-57.